DSC
AYTU icon

Daytona Street Capital’s AYTU BioPharma AYTU Stock Holding History

Daytona Street Capital’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4K Hold
10,000
– – 0.02% 215
2026
Q1 		$26.8K Hold
10,000
– – 0.02% 212
2025
Q4 		$26K Buy
+10,000
New +$22.4K 0.02% 228

Other funds holding AYTU

CAM
Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
BAM
Bellevue Asset Management Bellevue, Washington $217M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
VFM
Vision Financial Markets Stamford, Connecticut $115M AUM 18.96% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Daytona Street Capital's AYTU Position: Q2 2026 in Review

Daytona Street Capital held its AYTU BioPharma (AYTU) position steady in Q2 2026 at 10,000 shares worth $22.4K. The position accounts for 0.02% of the portfolio, ranked #215.

Daytona Street Capital first reported a position in AYTU in Q4 2025 and has held it in 3 quarters since. The position peaked at $26.8K in Q1 2026. 11 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

  • Daytona Street Capital held 10,000 shares of AYTU BioPharma worth $22.4K as of Q2 2026.
  • Daytona Street Capital left its AYTU BioPharma share count unchanged in Q2 2026.
  • AYTU BioPharma made up 0.02% of Daytona Street Capital's portfolio in Q2 2026, its #215 holding.
  • Daytona Street Capital first reported a position in AYTU BioPharma in Q4 2025 and has held it in 3 quarters since.
  • Daytona Street Capital's AYTU BioPharma position peaked at $26.8K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Daytona Street Capital's 13F filing for Q2 2026, filed 3 Aug 2026.